Navigation Links
New Edition of Definitive Resource in Tissue Engineering Released Today
Date:8/19/2007

Book Co-Edited by Advanced Cell Technology's Robert Lanza, MIT's Robert

Langer, and Harvard's Joseph Vacanti

WORCESTER, Mass., Aug. 16 /PRNewswire-FirstCall/ -- Three of the world's leading authorities in regenerative medicine, Robert Lanza, M.D., VP Research & Scientific Development for Advanced Cell Technology (OTC Bulletin Board: ACTC), Robert Langer, ScD, Institute Professor at MIT (recent recipient of the National Medal of Science), and Joseph Vacanti, MD, John Homans Professor at Harvard Medical School, have released the third edition of Principles of Tissue Engineering, the widely recognized definitive resource in the field of tissue engineering (Academic Press/Elsevier, August 15, 2007, Hardcover).

Principles of Tissue Engineering, Third Edition provides a much needed update of the rapid progress that has been achieved in the field, combining the prerequisites for a general understanding of tissue growth and development, the tools and theoretical information needed to design tissues and organs, as well as a presentation by the worlds experts of what is currently known about each specific organ system. The new edition includes greatly expanded focus on stem cells, including adult and embryonic stem cells and progenitor populations that may soon lead to new tissue engineering therapies for heart disease, diabetes, and a wide variety of other diseases that afflict humanity. This up-to-date coverage of stem cell biology and other emerging technologies is complemented by a series of new chapters on recent clinical experience in applying tissue engineering. The result is a comprehensive textbook that we believe will be useful to students and experts alike.

"Dr. Lanza is an industrial expert in the area of stem cells and regenerative medicine, with groundbreaking research that is widely respected throughout the scientific community," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "He has the unique ability to cut through the confusion and controversy, while articulating the issues and defining the benefits that surround the important research he and others are doing with embryonic stem cells for the betterment of humanity.

"Principles of Tissue Engineering, Third Edition includes contributions by almost 200 scientists and thought leaders, including Douglas Lauffenburger at the Massachusetts Institute of Technology, Bjorn Olsen at the Harvard Medical School, Robert Nerem at Georgia Institute of Technology, Alan Russell at the McGowan Institute for Regenerative Medicine, A. Hari Reddi at the University of California Davis, Ioannis Yannas at the Massachusetts Institute of Technology, George Whitesides at Harvard University, Alan Trounson at Monash Univeristy, Anthony Atala at the Wake Forest Institute for Regenerative Medicine, Charles Vacanti at Harvard Medical School and Massachusetts General Hospital, Eugene Bell at TEI Biosciences, and Laurie Zoloth at Northwestern University, among others.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

For more information, visit http://www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward- looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.


'/>"/>
SOURCE Advanced Cell Technology, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. UW Alzheimers researchers found company; privacy law; Science Expeditions
2. 2005 Madison-area tech directory includes more companies, resources
3. UW plans entrepreneurship program to link campus resources
4. Data Dimensions and MailSurity pool resources for digitizing paper mail
5. TeachingBooks brings free K-12 resources to Wisconsin residents
6. APIs labor resource management impacts 2,500 hospital employees
7. Grow Wisconsin resources for technology development
8. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
9. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
10. Simple Isolation of RNA from Tissue and Cultured Cells
11. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... spanning the full spectrum of drug and device development, and Prism Clinical ... companies and clinicians, today announced Verified Clinical Trials (VCT) has been ...
(Date:1/18/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface and ... suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers real-world ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016 /PRNewswire/ ... que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que ... de tumor en 2017, con múltiples sitios previstos a lo largo ... ... en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que ...
Breaking Biology News(10 mins):